Russian government changes procedure for launch of new drugs
The Russian Ministry of Health is changing the existing procedure for the launch of new drugs on the domestic market, with the aim to speed their withdrawal, according to recent statements by Veronika Skvortsova, Russia’s Minister of Health, reports The Pharma Letter’s local correspondent.
Under the terms of the plan, pharmaceutical manufacturers will be able to sell their drugs in Russia only after obtaining permission from the Russian Federal Service for the Supervision of Public Health and Social Development (Roszdravnadzor). Save
According to the current practice, the launch of new drugs in the Russian pharmaceutical market took place after the obtaining a certificate from accredited local test laboratories. However, according to state plans, these procedures are expected to be canceled due to their inconsistency with the requirements of Russian legislation, while the permissions for the launch of new drugs in the market will be provided by Roszdravnadzor.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze